Skip to main content

Adherence to Guidelines for Glucose Assessment in Starting Second-Generation Antipsychotics

Basic Details
Date
Monday, October 6, 2014
Type
Publication
Medical Product
aripiprazole
olanzapine
quetiapine
risperidone
second generation antipsychotic (SGA)
Health Outcome(s)
baseline glucose assessment
Description

This article describes the findings of a study conducted to evaluate baseline glucose assessment among youth ages 2 through 18 starting a second-generation antipsychotic in the United States.

Materials

Pediatrics, Volume 135, Issue 5, October 6, 2014, Pages e1308-1314, DOI: 10.1542/peds.2014-0828

Information
Time Period
2006 - 2011
Population / Cohort
All children 2 through 18 years of age
Data Source(s)
Mini-Sentinel Distributed Database (MSDD)
Related Assessment(s)
Final Report: Metabolic Effects Of Second Generation Antipsychotics In Youth
Sentinel Drug Assessment: Second Generation Antipsychotic Agents & Metabolic Effects in Children (Type 2 Diabetes, Metabolic Syndrome, Weight Gain)
Author(s)

Marsha Raebel PharmD, Robert Penfold PhD, Ann McMahon MD, MSc, Marsha Reichman PhD, Susan Shetterly MS, Glenn Goodrich MS, Susan Andrade ScD, Christoph Correll MD, Tobias Gerhard PhD

Corresponding Author

Marsha Raebel, Institute for Health Research, Kaiser Permanente Colorado, PO Box 378066, Denver, CO 80237, USA. Email: Marsha.A.Raebel@kp.org